The Neuroprotective Effect of Erythropoietin on Rotenone-Induced Neurotoxicity in SH-SY5Y Cells Through the Induction of Autophagy

Molecular Neurobiology

Volumn 53, Issue 6, 2016, Pages 3812-3821

  Jang, Wooyoung ^a,c   Kim, Hee Ju ^b,c   Li, Huan ^b   Jo, Kwang Deog ^a   Lee, Moon Kyu ^a   Yang, Hyun Ok ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Gangneung Asan Hospital   (South Korea)

Author keywords

Autophagy; Erythropoietin; Neuroprotection; Parkinson s disease

Indexed keywords

ADENYLATE KINASE; ALPHA SYNUCLEIN; BECLIN 1; BRAIN PROTEIN; ERYTHROPOIETIN; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN ULK 1; REACTIVE OXYGEN METABOLITE; ROTENONE; UNCLASSIFIED DRUG; LIGHT CHAIN 3, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; NEUROPROTECTIVE AGENT; NEUROTOXIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; INTRACELLULAR SIGNALING; MTT ASSAY; NEUROBLASTOMA CELL LINE; NEUROPROTECTION; NEUROTOXICITY; PROPIDIUM IODIDE ASSAY; PROTEIN EXPRESSION; SH SY5Y CELL LINE; CELL DEATH; DRUG EFFECTS; INTRACELLULAR SPACE; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ALPHA-SYNUCLEIN; APOPTOSIS; AUTOPHAGY; CELL DEATH; CELL LINE, TUMOR; ERYTHROPOIETIN; HUMANS; INTRACELLULAR SPACE; MICROTUBULE-ASSOCIATED PROTEINS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; REACTIVE OXYGEN SPECIES; ROTENONE; SIGNAL TRANSDUCTION;

EID: 84936864604     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9316-x     Document Type: Article

References (48)

1. Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132–144
2. Nutt JG, Wooten GF (2005) Diagnosis and initial management of Parkinson’s disease. N Engl Med 353:1021–1027
3. Lipski J, Nistico R, Berretta N, Guatteo E, Bernardi G, Mercuri NB (2011) l-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson’s disease? Prog Neurobiol 94:389–407
4. Schapira AV, Olanow C (2004) Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291:358–364
5. Banerjee R, Starkov AA, Beal MF, Thomas B (2009) Mitochondrial dysfunction in the limelight of Parkinson’s disease pathogenesis. Biochim Biophys Acta Mol Basis Dis 1792:651–663
6. Eriksen JL, Wszolek Z, Petrucelli L (2005) Molecular pathogenesis of Parkinson disease. Arch Neurol 62:353–357
7. Jellinger KA (2012) Neuropathology of sporadic Parkinson’ disease: evaluation and changes of concepts. Mov Disord 27:8–30
8. Xilouri M, Brekk O, Stefanis L (2013) Alpha-synuclein and protein degradation systems: a reciprocal relationship. Mol Neurobiol 47:537–551
9. Xiong N, Xiong J, Jia M, Liu L, Zhang X, Chen Z, Huang J, Zhang Z et al (2013) The role of autophagy in Parkinson’s disease: rotenone-based modeling. Behav Brain Funct 9:1–12
10. Glick D, Barth S, Macleod KF (2010) Autophagy: cellular and molecular mechanisms. J Pathol 221:3–12
11. Lynch-Day MA, Mao K, Wang K, Zhao M, Klionsky DJ (2012) The role of autophagy in Parkinson’s disease. Cold Spring Harbor Perspect Med 2:a009357
12. Tan C-C, Yu J-T, Tan M-S, Jiang T, Zhu X-C, Tan L (2014) Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy. Neurobiol Aging 35:941–957
13. Pan T, Kondo S, Le W, Jankovic J (2008) The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain 131:1969–1978
14. Pan T, Rawal P, Wu Y, Xie W, Jankovic J, Le W (2009) Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience 164:541–551
15. Winslow AR, Rubinsztein DC (2011) The Parkinson disease protein alpha-synuclein inhibits autophagy. Autophagy 7:429–431
16. Jang W, Kim HJ, Li H, Jo KD, Lee MK, Song SH, Yang HO (2014) 1,25-Dyhydroxyvitamin D3 attenuates rotenone-induced neurotoxicity in SH-SY5Y cells through induction of autophagy. Biochem Biophys Res Commun 451:142–147
17. Jelkmann W (1992) Erythropoietin: structure, control of production, and function. Physiol Rev 72:449–489
18. Brines M, Cerami A (2005) Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6:484–494
19. Adamcio B, Sargin D, Stradomska A, Medrihan L, Gertler C, Theis F, Zhang M, Muller M et al (2008) Erythropoietin enhances hippocampal long-term potentiation and memory. BMC Biol 6:37
20. Signore AP, Weng Z, Hastings T, Van Laar AD, Liang Q, Lee YJ, Chen J (2006) Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death. J Neurochem 96:428–443
21. Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M (2001) Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 276:39469–39475
22. Digicaylioglu M, Lipton S (2001) Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412:641–647
23. Kanaan NM, Collier TJ, Marchionini DM, McGuire SO, Fleming MF, Sortwell CE (2006) Exogenous erythropoietin provides neuroprotection of grafted dopamine neurons in a rodent model of Parkinson’s disease. Brain Res 1068:221–229
24. Xue YQ, Zhao LR, Guo WP, Duan WM (2007) Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson’s disease. Neuroscience 146:1245–1258
25. Jang W, Park J, Shin KJ, Kim J-S, Kim JS, Youn J, Cho JW, Oh E et al (2014) Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson’s disease. J Neurol Sci 337:47–54
26. Pedroso I, Bringas ML, Aguiar A, Morales L, Alvarez M, Valdés PA, Alvarez L (2012) Use of Cuban recombinant human erythropoietin in Parkinson’s disease treatment. MEDICC Rev 14:11–17
27. Bendix I, Schulze C, Haefen C, Gellhaus A, Endesfelder S, Heumann R, Felderhoff-Mueser U, Sifringer M (2012) Erythropoietin modulates autophagy signaling in the developing rat brain in an in vivo model of oxygen-toxicity. Int J Mol Sci 13:12939–12951
28. Yu Y et al (2013) Erythropoietin protects epithelial cells from excessive autophagy and apoptosis in experimental neonatal necrotizing enterocolitis. PLoS One 8:e69620
29. Xilouri M, Vogiatzi T, Stefanis L (2008) Alpha-synuclein degradation by autophagic pathways: a potential key to Parkinson’s disease pathogenesis. Autophagy 4:917–919
30. Xilouri M, Brekk OR, Kirik D, Stefanis L (2013) LAMP2A as a therapeutic target in Parkinson disease. Autophagy 9:2166–2168
31. Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L (2009) Aberrant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One 4:e5515
32. Choubey V, Safiulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M, Zharkovsky A, Kaasik A (2011) Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem 286:10814–10824
33. Gassmann M, Heinicke K, Soliz J, Ogunshola O, Marti H, Hofer T, Grimm C, Heinicke I et al (2003) Non-erythroid functions of erythropoietin. Adv Exp Med Biol 543:323–330
34. Juul S (2004) Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models. Clin Perinatol 31:129–142
35. Ehrenreich H, Bartels C, Sargin D, Stawicki S, Krampe H (2008) Recombinant human erythropoietin in the treatment of human brain disease: focus on cognition. J Ren Nutr 18:146–153
36. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, Siren A, Paulus W et al (2007) Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130:2577–2588
37. Kim J, Kundu M, Viollet B, Guan K-L (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13:132–141
38. Roach PJ (2011) AMPK → ULK1 → Autophagy. Mol Cell Biol 31:3082–3084
39. Park KH, Choi NY, Koh SH, Park HH, Kim YS, Kim MJ, Lee SJ, Yu HJ et al (2011) L-DOPA neurotoxicity is prevented by neuroprotective effects of erythropoietin. Neurotoxicology 32:879–887
40. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD et al (2005) Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122:927–939
41. Zhu Y, Zhao L, Liu L, Gao P, Tian W, Wang X, Jin H, Xu H et al (2010) Beclin 1 cleavage by caspase-3 inactivates autophagy and promotes apoptosis. Protein Cell 1:468–477
42. Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA, Robinson JP (2003) Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 278:8516–8525
43. Gibson SB (2013) Investigating the role of reactive oxygen species in regulating autophagy. Methods Enzymol 528:217–235
44. Lee SJ (2003) Alpha-synuclein aggregation: a link between mitochondrial defects and Parkinson’s disease? Antioxid Redox Signal 5:337–348
45. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC (2003) α-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278:25009–25013
46. Sridhar S, Botbol Y, Macian F, Cuervo AM (2012) Autophagy and disease: always two sides to a problem. J Pathol 226:255–273
47. Barmada SJ, Serio A, Arjun A, Bilican B, Daub A, Ando DM, Tsvetkov A, Pleiss M et al (2014) Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol 10:677–685
48. Martin DD, Ladha S, Ehrnhoefer DE, Hayden MR (2015) Autophagy in Huntington disease and huntingtin in autophagy. Trends Neurosci 38:26–35